Ubie Inc.

Ubie develops AI-driven healthcare diagnostics that help patients and healthcare professionals make informed decisions based on medical data. The company's technology aims to streamline the diagnostic process, providing insights that enhance patient care and improve health outcomes.

CCI Score

42.81

-0.03% April 18

Latest Event

Ubie Achieves 2 Million Uses of AI Symptom Checker in U.S.

Ubie's AI Symptom Checker has surpassed 2 million uses in the United States within its first year, bolstering partnerships with major pharmaceutical companies and promoting early disease detection and improved patient care.

Take Action

So what can you do? Support Ubie by shopping, spreading the word, or offering your support.

Shop Alternatives SEE ALL: Perceptive

RELEX

Hollo
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

DISSENTER

Ubie Inc. is currently rated as a Dissenter.

+25 to +44 CCI Score

These companies are vocal in their opposition to authoritarian regimes. They publicly criticize oppressive policies and engage in advocacy efforts to promote accountability and transparency, even if their actions aren’t as extensive as those of Moral Leaders.

Latest Events

DEC

04

2023

Ubie Achieves 2 Million Uses of AI Symptom Checker in U.S.
61.01

Ubie's AI Symptom Checker has surpassed 2 million uses in the United States within its first year, bolstering partnerships with major pharmaceutical companies and promoting early disease detection and improved patient care.
+70

Technology and Services Impact

April 12

The widespread adoption of Ubie's AI Symptom Checker demonstrates a significant positive impact in leveraging technology for enhanced healthcare outcomes. By facilitating early detection and prompting timely professional care, Ubie’s innovation supports community health and empowers patient decision-making, aligning with progressive values.

Ubie's AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships
APR

27

2023

Ubie Collaborates with Takeda for Digital Transformation in Healthcare
24.61

On April 27, 2023, Ubie Inc. entered into a comprehensive collaboration agreement with Takeda Pharmaceuticals to promote digital transformation in healthcare. The partnership will leverage Ubie's AI-driven diagnostic tools to aid in the early detection and management of rare and gastrointestinal diseases, aiming to streamline patient access to appropriate care.
+40

Technology and Services Impact

April 12

This rating reflects Ubie's proactive use of AI-driven technology to improve public health outcomes. The collaboration with Takeda Pharmaceuticals is a significant step in utilizing digital transformation to enhance early detection and diagnosis, which can be seen as a progressive investment in technology and services that benefit vulnerable patient populations.

Ubie signs a broad collaboration agreement with Takeda Pharmaceuticals to promote digital transformation
+20

Business Practices and Ethical Responsibility

April 12

The collaboration agreement demonstrates ethical business practices by partnering with a reputable pharmaceutical company to improve patient care pathways. By expanding its services and features to better serve patients and healthcare providers, Ubie shows a commitment to improving operational efficiency and promoting equitable access to healthcare.

Ubie signs a broad collaboration agreement with Takeda Pharmaceuticals to promote digital transformation